Patent intelligence · US
US 6827946
Compositions containing both sedative and non-sedative antihistamines
Compositions containing both sedative and non-sedative antihistamines
Patent details — US 6827946
- Jurisdiction
- US
- Status
- expired
- Grant date
- Dec 7, 2004
- Expiration
- Dec 2, 2024
- Applicant
- Collegium Pharmaceutical, Inc.
- Claims
- 29
- CPC classes
- A61K, A61K31/00, A61K45/06, A61K9/209
Quick answer
US 6827946 (Compositions containing both sedative and non-sedative antihistamines) is held by Collegium Pharmaceutical, Inc.. Status: expired. Granted Dec 7, 2004. Expires Dec 2, 2024 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Collegium Pharmaceutical, Inc.
- Grant date
- Expiration
- Claims
- 29
- CPC classes
- A61K, A61K31/00, A61K45/06, A61K9/209, A61K9/5084, A61P
More from Collegium Pharmaceutical, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 11191758
Use of selective serotonin 5-HT1A receptor agonists for treating side-effects of VMAT inhibitors
granted -
US 10668060
Tamper-resistant pharmaceutical compositions of opioids and other drugs
granted -
US 10646485
Process of making stable abuse-deterrent oral formulations
granted -
US 10525052
Abuse-deterrent drug formulations
granted -
US 10525053
Abuse-deterrent pharmaceutical compositions of opioids and other drugs
granted -
US 10188644
Process of making stable abuse-deterrent oral formulations
granted -
US 10004729
Tamper-resistant pharmaceutical compositions of opioids and other drugs
granted -
US 9968598
Process of making stable abuse-deterrent oral formulations
granted
Frequently asked questions
What is US patent 6827946?
US 6827946 (Compositions containing both sedative and non-sedative antihistamines) is held by Collegium Pharmaceutical, Inc.. Status: expired. Granted Dec 7, 2004. Expires Dec 2, 2024 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6827946?
Collegium Pharmaceutical, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 28 pharmaceutical patents for this assignee.
When does US 6827946 expire?
Our index shows an expiration date of Dec 2, 2024 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.